These markers allow for breast cancer tumors to be classified as hormone receptor positive (luminal A or B), HER2 overexpressing, or TN breast cancers, which do not express ER and PR and do not have HER2 amplification [3]. This evidence concerns the gene ERBB2 and breast cancer.